Reconstitution of CXCR3⁺ CCR6⁺ Th17.1-Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis.

ABSTRACT:

Background and objectives

Ofatumumab, a fully human anti-CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing-remitting multiple sclerosis (RRMS).

Methods

Seventeen RRMS patients were enrolled in this uncontrolled, prospective, observational cohort study (OMNISCIENCE study) and received regular subcutaneous ofatumumab treatments. Immune cell subsets were analyzed by single-cell mass cytometry at baseline and 6 months post-treatment. Peripheral blood monoclonal cells (PBMCs) from a separate cohort of treatment-naive RRMS patients were used for cytokine analysis through ex

SUBMITTER: Yang S 

PROVIDER: S-EPMC12093334 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature